Home PharmTech Gilead signs $34.5M deal for Hanmi/HHP’s I.V.-to-oral drug tech

Gilead signs $34.5M deal for Hanmi/HHP’s I.V.-to-oral drug tech

by Newsroom


To read the full story, subscribe or sign in.

Hanmi Pharmaceutical Co. Ltd. and Health Hope Pharma Ltd. may be getting a second wind for encequidar and the Orascovery platform, with Gilead Sciences Inc. picking up exclusive global rights to develop and commercialize encequidar in the field of virology for $2.5 million up front.

BioWorld BioWorld Asia Deals and M&A Cancer Endocrine/metabolic Small molecule Asia-Pacific



Source link

You may also like

About Us

Pharma Newswire™ aggregates, publishes and distributes news in the Pharmaceutical Industry. In association with EmailWire, Pharma Newswire™ provides press release distribution services in the pharmaceutical sector. Press releases are disseminated to journalists, experts, investors, trade publications and other related media outlets. To send a press release, contact us through the following messaging apps:

Pharma Newswire™ is part of GroupWeb Media Network. © 2025 GroupWeb Media LLC